Related Experiment Video
Updated: Oct 15, 2025
12:04
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
Published on: March 10, 2023
3.9K
Genomic Engineering in Human Hematopoietic Stem Cells: Hype or Hope?
Stefanie Klaver-Flores1, Hidde A Zittersteijn2, Kirsten Canté-Barrett1
1Department of Immunology, Leiden University Medical Center, Leiden, Netherlands.
Frontiers in Genome Editing
|October 29, 2021
Summary
Gene editing primary cells, especially hematopoietic stem cells (HSCs), faces challenges like low efficiency and accessibility. Overcoming these hurdles is crucial for developing effective gene therapies for blood disorders.
Area of Science:
- Biotechnology
- Molecular Biology
- Gene Therapy
Background:
- Transformed cell lines differ significantly from primary cells in key aspects like transfection efficiency and chromatin accessibility.
- Current gene editing tools are often optimized for cell lines, not primary cells, limiting their therapeutic application.
Purpose of the Study:
- To review the challenges and discuss the future of gene editing in primary cells, particularly hematopoietic stem cells (HSCs).
- To highlight obstacles in developing novel genetic engineering therapies for monogenic blood and immune disorders.
Main Methods:
- Review of current gene editing techniques and their limitations in primary cells.
- Discussion of strategies to improve gene editing efficiency and delivery in hematopoietic stem cells (HSCs).
Main Results:
- Low gene editing efficiency in primary cells remains a significant obstacle for therapeutic applications.
- Accessibility of therapeutic target genes in hematopoietic stem cells (HSCs) is limited due to heterochromatin structure.
- Off-target and on-target side effects pose safety concerns for clinical gene editing in HSCs.
Conclusions:
- Significant challenges persist in applying gene editing to hematopoietic stem cells (HSCs) for clinical gene correction.
- Further research and development are needed to overcome technical and safety barriers for genetic engineering therapies targeting blood and immune disorders.
